Skip to main content
Erschienen in: PharmacoEconomics 9/2013

01.09.2013 | Leading Article

Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?

verfasst von: Christopher McCabe, Richard Edlin, Peter Hall

Erschienen in: PharmacoEconomics | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Healthcare systems are increasingly under pressure to provide funding for innovative technologies. These technologies tend to be characterized by their potential to make valued contributions to patient health in areas of relative unmet need, and have high acquisition costs and uncertainty within the evidence base on their actual impact on health. Decision makers are increasingly interested in linking reimbursement strategies to the degree of uncertainty in the evidence base and, as a result, reimbursement for innovative technologies is frequently linked to some form of patient access or risk-sharing scheme. As the dominant methods of economic evaluation report final outcomes only at the time horizon of the analysis, they present only aggregated information. This omits much of the information available on how net benefit is distributed within the time horizon. In this article, we introduce the Net Benefit Probability Map (NBPM), which maps net health benefit versus time to identify how certain decision makers can be about the benefit of technologies at multiple time points. Using an illustrative example, we show how the NBPM can inform decision makers about how long it will take for innovative technologies to ‘pay off’, how methodological choices on discount rates affect results and how alternative payment mechanisms can reduce the risk for decision makers facing innovative technologies.
Literatur
1.
Zurück zum Zitat Van Hout B, Al J, Gordon G, Rutten F. Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994;3(5):309–19.PubMedCrossRef Van Hout B, Al J, Gordon G, Rutten F. Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994;3(5):309–19.PubMedCrossRef
2.
Zurück zum Zitat Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
3.
Zurück zum Zitat Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87.PubMedCrossRef Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87.PubMedCrossRef
4.
Zurück zum Zitat Eckermann S, Willan A. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. Pharmacoeconomics. 2011;29(7):563–77.PubMed Eckermann S, Willan A. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. Pharmacoeconomics. 2011;29(7):563–77.PubMed
6.
Zurück zum Zitat Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, et al. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health. Centre for Health Economics Research Paper 69. York: University of York; 2011. Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, et al. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health. Centre for Health Economics Research Paper 69. York: University of York; 2011.
7.
Zurück zum Zitat Stafinski T, McCabe C, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into health care systems. Pharmacoeconomics. 2010;28(2):113–42.PubMedCrossRef Stafinski T, McCabe C, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into health care systems. Pharmacoeconomics. 2010;28(2):113–42.PubMedCrossRef
9.
Zurück zum Zitat Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study of the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment Programme. Health Technol Assess. 2004;8(31):1–103. Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study of the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment Programme. Health Technol Assess. 2004;8(31):1–103.
10.
Zurück zum Zitat Hall P, Edlin R, Kharroubi S, Gregory W, McCabe C. Expected net present value of information: from burden to investment. Med Decis Mak. 2012;32(3):E11–21.CrossRef Hall P, Edlin R, Kharroubi S, Gregory W, McCabe C. Expected net present value of information: from burden to investment. Med Decis Mak. 2012;32(3):E11–21.CrossRef
11.
Zurück zum Zitat Hall P, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron D. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering long-term toxicity and patterns of recurrence. Pharmacoeconomics. 2011;29(5):415–32.PubMedCrossRef Hall P, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron D. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering long-term toxicity and patterns of recurrence. Pharmacoeconomics. 2011;29(5):415–32.PubMedCrossRef
12.
Zurück zum Zitat Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Mak. 1998;18(2):S68–90.CrossRef Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Mak. 1998;18(2):S68–90.CrossRef
13.
Zurück zum Zitat Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer A. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2010;20:2–15. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer A. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2010;20:2–15.
14.
Zurück zum Zitat Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570–9.PubMedCrossRef Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570–9.PubMedCrossRef
15.
Zurück zum Zitat McCabe C, Edlin R, Stafinski T, Menon D. Access with evidence development schemes: a framework for design and evaluation. Pharmacoeconomics. 2010;28(2):143–52.PubMedCrossRef McCabe C, Edlin R, Stafinski T, Menon D. Access with evidence development schemes: a framework for design and evaluation. Pharmacoeconomics. 2010;28(2):143–52.PubMedCrossRef
16.
Zurück zum Zitat Brouwer W, Niessen L, Postma M, Rutten F. Need for differential discounting of costs and health effects in cost effectiveness analyses. Br Med J. 2005;331:446–8.CrossRef Brouwer W, Niessen L, Postma M, Rutten F. Need for differential discounting of costs and health effects in cost effectiveness analyses. Br Med J. 2005;331:446–8.CrossRef
17.
Zurück zum Zitat Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, et al. Discounting and cost-effectiveness in NICE: stepping back to sort out a confusion. Health Econ. 2006;15(1):1–4.PubMedCrossRef Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, et al. Discounting and cost-effectiveness in NICE: stepping back to sort out a confusion. Health Econ. 2006;15(1):1–4.PubMedCrossRef
18.
Zurück zum Zitat Jonsson P, Roberts J. Briefing paper for the methods review group working party on discounting. London: National Institute for Health and Clinical Excellence; 2011. Jonsson P, Roberts J. Briefing paper for the methods review group working party on discounting. London: National Institute for Health and Clinical Excellence; 2011.
20.
Zurück zum Zitat Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed? Br Med J. 2008;336(7638):251–4.CrossRef Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed? Br Med J. 2008;336(7638):251–4.CrossRef
21.
Zurück zum Zitat O’Brien B, Briggs A. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002;11(6):455–68.PubMedCrossRef O’Brien B, Briggs A. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002;11(6):455–68.PubMedCrossRef
22.
Zurück zum Zitat NICE. Guide to the methods of health technology. London: National Institute for Health and Clinical Excellence; 2008. NICE. Guide to the methods of health technology. London: National Institute for Health and Clinical Excellence; 2008.
Metadaten
Titel
Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?
verfasst von
Christopher McCabe
Richard Edlin
Peter Hall
Publikationsdatum
01.09.2013
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 9/2013
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0077-y

Weitere Artikel der Ausgabe 9/2013

PharmacoEconomics 9/2013 Zur Ausgabe